drugset / Trial / NCT03597347
Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A study to evaluate the efficacy of inhaled molgramostim administered open-label to adult cystic fibrosis (CF) subjects with chronic pulmonary nontuberculous mycobacterial (NTM) infection, with or without ongoing antimycobacterial guideline based combination therapy.
Timeline
- Start
- 2019-06-20
- Primary completion
- 2020-10-02
- Completion
- 2020-10-02
Outcome
Outcome not reported
Stopped (Enrollment): “Recruitment for trial stopped early due to limitations from COVID-19, additionally changes in the standard of care for CF patients during the study period resulted in confounding of the primary endpoint.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Molgramostim | Protein / enzyme biologic | 300 ug | Inhaled |